News | Contrast Media | November 14, 2018

Voyageur Minerals to Begin Manufacturing Barium Contrast Products With Chief Medical Supply

Joint venture will bring new barium sulfate contrast products to the high-value Canadian market

Voyageur Minerals to Begin Manufacturing Barium Contrast Products With Chief Medical Supply

November 14, 2018 — Voyageur Minerals Ltd. signed a joint venture agreement with Chief Medical Supply Ltd (CM) of Calgary, Alberta to engage in the development, marketing and commercialization of human and animal radiographic contrast agents and related pharmaceutical products. The agreement will focus on development of barium sulfate contrast products.

The joint venture will provide Voyageur with the opportunity to penetrate the highest value barium sulfate market in the world. Management anticipates that cash flow from this line of business will begin in 2019.

In the terms of the agreement:

  • Voyageur will provide up to 2,000 metric tons annually of USP grade barium sulfate API, to the joint venture at no cost to the Joint Venture;
  • CM will provide the Canadian regulatory approval, the formulation, manufacturing, testing and packaging of the barite suspension products, using its own facilities and equipment, at no cost to the joint venture; and
  • All other activities in respect to regulatory approvals, marketing and sales of the products will be for the account of the joint venture, and the costs of such will be a direct charge against the revenues of the joint venture.

The joint venture will begin formulation of its product lines and move forward with applications for Health Canada drug identification number registration. The target for initial sales is the second quarter of 2019. Initial sales of the product will focus on Canada utilizing the Health Canada bidding process. After sales into the Canadian market have commenced, the joint venture will apply for certification and begin sales into Europe and the rest of the world, excluding the United States. Approval for sale in the United States requires approval through the U.S. Food and Drug Administration (FDA). This process will take a year or more before sales can begin in the United States.

The joint venture plans on targeting markets with government-run healthcare systems and private clinics.                 

For more information: www.voyageurminerals.ca

Related Content

Guerbet presented its Contrast&Care injection management solution at ECR 2018

News | Contrast Media | November 13, 2019
November 13, 2019 – Guerbet, a global specialist in...
Windsong Radiology Group

Windsong Radiology Group

Sponsored Content | Case Study | Contrast Media Injectors | October 30, 2019
Windsong Radiology Group is a New York-based radiolo
Bayer Introduces Medrad Stellant Flex CT Injection System
Technology | Contrast Media Injectors | September 11, 2019
Bayer announced the introduction of the Medrad Stellant Flex computed tomography (CT) injection system. Stellant Flex...
Characteristics nephrologists associate with renal high-risk patients. (n=13)

Characteristics nephrologists associate with renal high-risk patients. (n=13)

Feature | Contrast Media | September 05, 2019
The global rise in chronic disease has significantly increased demand for diagnostic imaging procedures, and in turn,
News | Contrast Media | September 03, 2019
Researchers in South Korea have found that patients with family and personal history of allergic reactions to contrast...
Displacement comparison at the end-systolic frame and final frame

Displacement comparison at the end-systolic frame and final frame. The three patients (V6, V10, V16) with different left-ventricle walls are shown. Point-to-surface distance is a measure to estimate the distance of a point from the reference surface. Image courtesy of WMG, University of Warwick

News | Cardiac Imaging | August 28, 2019
A new 3-D magnetic resonance imaging (MRI) computing technique developed by scientists in WMG at the University of...
Some Pregnant Women Are Exposed to Gadolinium in Early Pregnancy
News | Women's Health | August 20, 2019
A small but concerning number of women are exposed to a commonly used magnetic resonance imaging (MRI) contrast agent...
Contrast Use in First Transthoracic Echocardiogram for Heart Failure Reduces Repeat Testing
News | Cardiovascular Ultrasound | August 07, 2019
Heart failure is the fourth most common cause for all admission to U.S. hospitals, and it is the most common reason for...